Bank of America Raises Phibro Animal Health (NASDAQ:PAHC) Price Target to $27.00

Phibro Animal Health (NASDAQ:PAHC) had its price objective increased by Bank of America from $19.00 to $27.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage currently has an “underperform” rating on the stock. Bank of America‘s price objective suggests a potential downside of 27.16% from the company’s previous close.

PAHC has been the topic of several other reports. JPMorgan Chase & Co. raised Phibro Animal Health from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $25.00 to $35.00 in a research note on Monday, July 7th. BNP Paribas raised Phibro Animal Health to a “hold” rating in a research note on Monday, June 16th. Wall Street Zen raised Phibro Animal Health from a “hold” rating to a “buy” rating in a research report on Friday, May 9th. Morgan Stanley set a $34.00 price target on Phibro Animal Health in a research report on Thursday. Finally, BNP Paribas Exane raised Phibro Animal Health from an “underperform” rating to a “neutral” rating and set a $24.00 price target on the stock in a research report on Monday, June 16th. One investment analyst has rated the stock with a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Reduce” and an average target price of $28.40.

Phibro Animal Health Stock Performance

NASDAQ PAHC opened at $37.07 on Friday. The firm has a market capitalization of $1.50 billion, a P/E ratio of 31.42, a P/E/G ratio of 0.54 and a beta of 0.80. Phibro Animal Health has a 1-year low of $16.16 and a 1-year high of $38.83. The company has a debt-to-equity ratio of 2.46, a current ratio of 2.76 and a quick ratio of 1.23. The business’s 50-day simple moving average is $29.34 and its 200-day simple moving average is $24.45.

Phibro Animal Health (NASDAQ:PAHC) last released its quarterly earnings data on Wednesday, August 27th. The company reported $0.57 earnings per share for the quarter, beating the consensus estimate of $0.52 by $0.05. The business had revenue of $378.70 million for the quarter, compared to analyst estimates of $362.24 million. Phibro Animal Health had a return on equity of 32.14% and a net margin of 3.73%. Phibro Animal Health has set its FY 2026 guidance at 2.520-2.700 EPS. Equities analysts predict that Phibro Animal Health will post 1.95 EPS for the current year.

Institutional Investors Weigh In On Phibro Animal Health

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. increased its holdings in Phibro Animal Health by 0.4% during the 1st quarter. Vanguard Group Inc. now owns 1,521,520 shares of the company’s stock worth $32,500,000 after purchasing an additional 6,784 shares during the last quarter. Acadian Asset Management LLC increased its holdings in Phibro Animal Health by 0.5% during the 1st quarter. Acadian Asset Management LLC now owns 782,939 shares of the company’s stock worth $16,713,000 after purchasing an additional 4,144 shares during the last quarter. Nuveen Asset Management LLC increased its holdings in Phibro Animal Health by 21.4% during the 4th quarter. Nuveen Asset Management LLC now owns 588,001 shares of the company’s stock worth $12,348,000 after purchasing an additional 103,618 shares during the last quarter. Geode Capital Management LLC increased its holdings in Phibro Animal Health by 1.4% during the 2nd quarter. Geode Capital Management LLC now owns 554,927 shares of the company’s stock worth $14,175,000 after purchasing an additional 7,841 shares during the last quarter. Finally, Nuveen LLC bought a new stake in shares of Phibro Animal Health in the 1st quarter valued at approximately $10,312,000. 99.34% of the stock is currently owned by hedge funds and other institutional investors.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.